Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 7/20 | 0.53 |
| ▸ | MGLL | Q99685 | 8/20 | 0.45 |
| ▸ | FASN | P49327 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729440 | 0.94 | PROKR1 (0.44) | PROKR1MGLLFASN | |
| SCHEMBL22729425 | 0.90 | TP53 (0.47) | MGLLLMNATP53 | |
| SCHEMBL22755306 | 0.85 | PROKR1 (0.52) | PROKR1MGLLFASNLMNATP53 | |
| SCHEMBL22729673 | 0.84 | ALDH1A1 (0.47) | PROKR1MGLLLMNATP53MYC | |
| SCHEMBL22729626 | 0.83 | ALDH1A1 (0.47) | LMNA | |
| SCHEMBL22729510 | 0.81 | CCNC (0.42) | PROKR1CCNCCDK8 | |
| SCHEMBL23116397 | 0.81 | HRH1 (0.42) | PROKR1MGLL | |
| SCHEMBL22729580 | 0.81 | SPR (0.41) | MGLLLMNATP53 | |
| SCHEMBL22729772 | 0.80 | ALDH1A1 (0.42) | MGLLLMNATP53 | |
| SCHEMBL29839360 | 0.80 | ALDH1A1 (0.42) | MGLLLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | PROKR1 3517/4885MGLL 92/4885FASN 1169/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | PROKR1 3556/4885MGLL 91/4885FASN 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.